Global Gastric Cancer Therapy Market - Segmented by Therapy Type, End-User, and Geography - Growth, Trends, and Forecast (2018 - 2023)

  • ID: 4591665
  • Report
  • Region: Global
  • 112 pages
  • Mordor Intelligence
1 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • Eli Lilly And Company
  • F. Hoffmann-La Roche Ltd
  • Glaxosmithkline Plc
  • Imugene Limited
  • Merck Kgaa
  • MORE
The global gastric cancer therapy market is expected to register a CAGR of 13.0% during the forecast period (2018 - 2023). Asia Pacific dominates the market, due to the growing incidence of gastric cancer in that region.

Growing Incidence of Gastric Cancer

According to a report published by Indian Council of Medical Research in 2014, gastric cancer is the fourth leading cancer in the world, accounting for 736,000 deaths. Around 1 million new cases of gastric cancer and 0.7 million deaths due to gastric cancer are reported every year. Age-standardized incidence rates are approximately twice as high in men as in women. Presently, gastric cancer is more common in Asia, than in the United States or Europe. Notably, 42% of cases occur in China alone.

Thus, increasing incidence of gastric cancer, coupled with strong drug pipeline, and introduction of novel therapies for metastatic stomach cancer, across the world, are likely to drive the market for gastric cancer therapy.

High Cost of Cancer Therapy and Side Effects of Cancer Drugs

The global cost of cancer therapy and drugs increased from USD 91 billion to USD 113 billion, in 2016. High cost of therapy and adverse events associated with the existing cancer drugs, for treatment of stomach cancer, may hinder the global stomach cancer market. The serious side effects associated with the usage of drugs include autoimmune reactions and infusion reactions. Additionally, a large patient pool undiagnosed with gastric cancer and the lack of awareness regarding gastric cancer are likely to impede the growth of the global cancer therapy market.

Asia-Pacific to Dominate the Market

Asia-Pacific dominates the global gastric cancer therapy market, owing to high incidence of stomach cancer in that region. China is expected to show a tremendous growth for this market, during the forecast period, owing to factors, such as high prevalence of obesity, and growing awareness about diabetes care. The growing incidence of gastric cancer in China is followed by Japan and Korea. China accounts for over 40% of all new gastric cancer cases in the world, which will drive the market for gastric cancer therapy in China.

Key Developments in the Market
  • February 2018: Imugene, an immune oncology company announced that its cancer vaccine yields promising results in gastric cancer clinical trial studies.
  • September 2017: The Food and Drug Administration (FDA) approved the immunotherapy drug pembrolizumab(Keytruda®) to be used on patients with advanced gastric (stomach) cancer.
Major Players: BRISTOL-MYERS SQUIBB, ELI LILLY AND COMPANY, F. HOFFMANN-LA ROCHE LTD, GLAXOSMITHKLINE PLC, IMUGENE LIMITED, MERCK KGAA, NOVARTIS AG, ONO PHARMACEUTICALS, OTSUKA HOLDINGS CO. LTD, AND SANOFI amongst others.

Reasons to Purchase the Report
  • Current and future market outlook for gastric cancer therapy in the developed and emerging markets
  • Analyse various perspectives on the market, with the help of Porter’s five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness the fastest growth, during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • 3 month analyst support, along with the market estimate sheet (in Excel)
Customization of the Report

This report can be customized to meet your requirements.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • Eli Lilly And Company
  • F. Hoffmann-La Roche Ltd
  • Glaxosmithkline Plc
  • Imugene Limited
  • Merck Kgaa
  • MORE
1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Growing Incidence of Gastric Cancer
6.1.2 Rise Cancer Treatment Center
6.1.3 Strong Product Pipeline
6.1.4 Introduction of Novel Therapies for Metastatic Stomach Cancer
6.2 Market Restraints
6.2.1 High Cost of Cancer Therapy and Side Effects of Cancer Drugs
6.2.2 Lack of Awareness Regarding Gastric Cancer
6.3 Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 By Therapy Type
7.1.1 Surgery
7.1.2 Chemotherapy
7.1.3 Targeted Therapy
7.1.3.1 Sunitinib
7.1.3.2 Trastuzumab
7.1.3.3 Imatinib
7.1.4 Immuno Therapy
7.1.5 Radiation Therapy
7.2 By End-users
7.2.1 Hospitals and Specialty Clinics
7.2.2 Cancer Research and Treatment Centers
7.2.3 Ambulatory Surgery Centers
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia
7.3.3.5 New Zealand
7.3.3.6 South Korea
7.3.3.7 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America

8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches

9. Key Players
9.1 Bristol-Myers Squibb
9.2 Eli Lilly and Company
9.3 F. Hoffmann-La Roche Ltd
9.4 GlaxoSmithKline PLC
9.5 Imugene Limited
9.6 Merck KGaA
9.7 Novartis AG
9.8 Ono Pharmaceuticals
9.9 Otsuka Holdings Co. Ltd
9.10 Sanofi
9.11 List Not Exhaustive

10. Future of the Market
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Bristol-Myers Squibb
  • Eli Lilly And Company
  • F. Hoffmann-La Roche Ltd
  • Glaxosmithkline Plc
  • Imugene Limited
  • Merck Kgaa
  • Novartis Ag
  • Ono Pharmaceuticals
  • Otsuka Holdings Co. Ltd
  • Sanofi
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll